Sun Pharma’s Organon Deal

Sun Pharma’s $11.75 billion acquisition of Organon helps establish that Indian pharma can credibly build a global, specialty‑care platform through bold, cash‑powered M&A. For Indian pharma CXOs and investors, this deal is a reset of sorts. It is no longer “if” but “how and where” the next wave of scale‑creating acquisitions will land, both globally and in domestic consolidation plays like Mankind‑BSV or Torrent‑JB Pharma‑type combinations.Yet, as balance sheets bulge with cash, there’s a risk that boards will prioritise M&A momentum over long‑cycle innovation, pushing back R&D agendas by years. Will pharma strike a barbell strategy using acquisitions to buy scale and commercial muscle, while ring‑fencing capital to focus on next‑generation pipelines especially in biologics, and specialty care? This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit mypharmareviews.substack.com